Prior Bad Conduct By Pharma Companies Could Be ‘Plus Factor’ In Merger Review

Experts suggest US FTC and DOJ retrospectively assess whether a merger gives companies increased leverage with PBMs and consider how it will impact vulnerable communities. Rutger’s Michael Carrier says there should be a presumption against mergers between two large firms.

M&A image
Past anticompetitive behaviour of pharma companies could influence FTC merger analysis • Source: Shutterstock

More from Compliance

More from Pink Sheet